We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Catco Reinsurance Opportunities Fund Limited | LSE:CAT | London | Ordinary Share | BMG1961Q3242 | ORD USD0.00013716 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 25.00 | 14.00 | 36.00 | 25.00 | 25.00 | 25.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 6.33M | 5.44M | 3.6440 | 6.86 | 37.33M |
RNS No 5920t CAMBRIDGE ANTIBODY TECHNOLOGY GROUP 24th March 1999 STRENGTHENS INTELLECTUAL PROPERTY POSITION FUNDAMENTAL HUMAN ANTIBODY PATENT GRANTED IN US Melbourn, UK... Cambridge Antibody Technology ("CAT") has been granted a US patent with broad claims covering human antibodies to human proteins isolated by phage display. The key significance of the patent is that it covers the isolation of human antibodies against all human proteins, except for those that generate natural antibodies in humans. Targets for drugs designed to treat many human diseases will often be such human proteins, particularly as future drug targets emerge from human genome initiatives. Dr David Chiswell, Chief Executive Officer of CAT, commenting on today's announcement, said: "This provides CAT with a fundamental US patent which significantly strengthens our intellectual property position in the US and adds to our patent portfolio in both the US and Europe covering the isolation of monoclonal antibodies by phage display. In particular, the patent's broad coverage, of human antibodies that bind human proteins, underpins our business strategy of developing a broad pipeline of human antibody based therapeutic products." This patent, No. US 5,885,793, entitled "Production of Anti-Self Antibodies from Antibody Segment Repertoires and Displayed on Phage" arises from work carried out by the Medical Research Council ('MRC') and CAT. This work demonstrated that human antibody fragments directed against human proteins could be isolated from human antibody phage display libraries constructed from non-immunised humans. An equivalent Australian patent has already been granted, with European and Japanese filings currently under examination. END MSCPBUCPWBGBGMW
1 Year Catco Reinsurance Opport... Chart |
1 Month Catco Reinsurance Opport... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions